Actively Recruiting
Evaluation of PLN-101095 Combined With Pembrolizumab for Adults With Advanced or Metastatic Solid Tumors After Progression on Immunotherapy
Led by Pliant Therapeutics, Inc. · Updated on 2026-10-02
124
Participants Needed
22
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating PLN-101095 combined with pembrolizumab in adults with advanced or metastatic solid tumors that have progressed despite prior pembrolizumab treatment. This Phase 1a1b open-label study aims to assess the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and early signs of antitumor activity of this combination in patients with documented resistance to immune checkpoint inhibitors. The study includes two parts Part 1 involves consecutive dose-escalation cohorts of PLN-101095 at varying doses 250 mg to 2000 mg, administered twice or three times daily combined with pembrolizumab given intravenously every three weeks. Part 2 expands dosing cohorts to evaluate the combination and PLN-101095 monotherapy in specific tumor types, including non-small cell lung cancer, clear cell renal cell carcinoma, and tumor mutational burden-high solid tumors. Participants undergo treatment cycles with regular safety and tumor assessments, including monitoring of side effects and drug levels. Researchers will measure outcomes such as safety and tolerability from first dose through 16 weeks post-treatment, as well as antitumor activity until disease progression or death. The study spans up to several years, with ongoing evaluations to understand the treatments effects and duration of response.
CONDITIONS
Brief Title
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Research Team
P
Pliant Therapeutics Medical Monitor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here